Zydus Lifesciences zooms on launching Bemdac to treat uncontrolled LDL-c
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 343.45, up by 10.00 points or 3.00% from its previous closing of Rs. 333.45 on the BSE.
The scrip opened at Rs. 335.00 and has touched a high and low of Rs. 344.45 and Rs. 335.00 respectively. So far 48128 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 668.85 on 11-Jun-2021 and a 52 week low of Rs. 319.40 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 344.45 and Rs. 319.40 respectively. The current market cap of the company is Rs. 35104.13 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 15.44% and 9.69% respectively.
Zydus Lifesciences has launched Bemdac (Bempedoic acid), a new class of drug for the first time in India. The oral drug ushers in a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite life-style modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management. Bemdac is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol.
LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases.
Zydus Lifesciences operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
